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A 62-year-old woman received RBX2660, an investigational 
microbiome restoration therapeutic, for recurrent multidrug-
resistant (MDR) urinary tract infection (UTI). RBX2660 
increased gut microbiome diversity but did not eliminate 
uropathogen carriage, and MDR UTI recurred after subse-
quent antibiotic exposure. Thus, restoration of microbiome di-
versity does not preclude disease recurrence by residual MDR 
pathogens.
Keywords.  antibiotic resistance; fecal microbiota trans-
plant; microbial restoration therapy; microbiome; urinary tract 
infection.
Urinary tract infections (UTIs) are among the most common 
bacterial infections, affecting ~150 million people annually, 
and are predominantly caused by uropathogenic Escherichia 
coli and other Enterobacteriaceae [1]. Serious sequelae include 
pyelonephritis, increased risk of preterm birth, and sepsis. 
Effective treatment of UTIs is complicated by increasing rates 
of antibiotic resistance and the propensity of uropathogens to 
establish and disseminate from gastrointestinal reservoirs, con-
tributing to symptomatic recurrence in 30%–50% of patients [1, 
2]. Recurrence frequently leads to repeated cycles of antibiotic 
treatment and resistance, culminating in exposure to antibiotics 
of last resort and/or multidrug resistance. Accordingly, novel 
approaches for effective elimination of multidrug-resistant 
(MDR) uropathogens from their gastrointestinal niches are of 
tremendous clinical significance.
Intestinal microbial restoration by fecal microbiota trans-
plant (FMT) is an emerging treatment for patients colonized 
with enteric multidrug-resistant organisms (MDROs), in-
cluding uropathogens [3]. FMT has been shown to decolo-
nize uropathogenic MDR Klebsiella pneumoniae, Pseudomonas 
aeruginosa, and E.  coli from the gut, often as an incidental 
outcome of Clostridioides difficile treatment [4–7]. However, 
existing studies are limited by a lack of microbiome analysis be-
fore and after FMT, an absence of uropathogen monitoring and 
clonal tracking, or, in most cases, both. Such context is essential 
to assessing the impact of intestinal microbial restoration and 
determining whether an MDRO has been successfully cleared 
from its reservoir(s).
Here we present the case of a 62-year-old woman with re-
current UTI and a complex medical history, including liver and 
kidney transplantation, diabetes, and lymphoma, who received 
RBX2660, an investigative intestinal microbiome restoration 
product derived from human stool [8, 9], for prevention of re-
current MDR UTI. We contextualize her clinical progression 
following RBX2660 with genotypic and phenotypic analyses of 
microbiome composition and within-host MDRO evolution. 
Administration of RBX2660 resulted in a considerable increase 
in intestinal microbiome diversity, as well as an MDR UTI–free 
period, but not complete eradication of the causative MDR 
uropathogen. Subsequent exposure to broad-spectrum anti-
biotics for an unrelated infection was followed by recurrence 
of MDR UTI.
This case report illustrates an important challenge for the de-
velopment of microbiota restoration therapies: patients in need 
of such therapies are highly vulnerable and likely to receive anti-
biotics, but those same antibiotics can select for MDROs that 
were incompletely eliminated by FMT. Thus, complete MDRO 
eradication from a patient’s microbiome (ie, undetectable car-
riage) may be a prerequisite for the long-term clinical success of 
microbiota restoration therapies.
CASE REPORT
The patient was a 62-year-old woman with a history of kidney 
and liver transplantation in 2009, diffuse large B-cell lym-
phoma (DLBCL), diabetes mellitus, peripheral vascular dis-
ease, gout, chronic lung disease, and recurrent UTIs due to 
MDR K. pneumoniae. The patient was enrolled in clinical trial 
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#NCT02312986 (“FMT for Multidrug Resistant Organism 
Reversal”) and received RBX2660 in September 2015 for in-
testinal uropathogen decolonization. Before intervention, the 
patient’s most recent UTI episodes occurred in November 2013 
(treated with meropenem, then ertapenem, then fosfomycin), 
January 2014 (onset 5 days after fosfomycin was stopped for a 
previous UTI), and June 2014 (onset 7 weeks after ertapenem 
was stopped for a previous UTI). Due to the frequency and 
severity of her UTI recurrences, she remained on suppres-
sive ertapenem from her last UTI until 2 days before receiving 
RBX2660 in September 2015.
RBX2660 has been evaluated in clinical trials to prevent re-
current C. difficile infection [8, 9] and was administered as per 
manufacturer guidelines. The patient tolerated the study proce-
dure (enema) and study product (RBX2660) without significant 
adverse events. The patient remained free of urinary symptoms 
until October 2015, ~7 weeks post-FMT, when she developed 
a UTI from Proteus mirabilis that resolved with 7 days of oral 
amoxicillin. In December 2015, the patient developed toe gan-
grene related to preexisting conditions of gout, diabetes mel-
litus, and peripheral vascular disease, requiring treatment 
with broad-spectrum antibiotics and ultimately amputation. 
The patient had a K.  pneumoniae UTI recurrence in January 
2016, ~19 weeks post-FMT, which was treated with ertapenem. 
In April 2016, the patient had a single episode of fever, and a 
urine culture was sent. The culture grew an ertapenem-resistant 
K. pneumoniae, but the patient did not manifest UTI symptoms, 
and a repeat urine culture was negative. Ertapenem was con-
tinued until the patient died from complications of squamous 
cell carcinoma in December 2016.
The patient’s medical history over the study period is sum-
marized in Figure  1A and comprehensively described in the 
Supplementary Data.
METHODS
Study protocols and analyses are described in the Supplementary 
Data.
RESULTS
RBX2660 Modulated Microbiome Composition
Before RBX2660 intervention for chronically recurrent UTI, 
the patient exhibited a dysbiotic microbiome characteristic of 
prolonged antibiotic exposure, including low species richness 
and high abundance of antibiotic resistance genes (ARGs). 
After RBX2660 administration, increased species richness, al-
tered community composition, and reduced ARG carriage were 
observed. Relative to the pre-RBX2660 baseline (16 species), 
species richness more than doubled by 1 month post-RBX2660 
(40 species), and by 4 months post-FMT, richness approached 
that of RBX2660 preparation (51 and 60 species, respec-
tively) (Figure 1B). Several typically rare taxa that were highly 
abundant pre-RBX2660, including Erysipelotrichaceae and 
Subdoligranulum, were largely replaced by the more traditional 
commensals Bacteroides and Ruminococcus after RBX2660 
(Figure 1B). The relative abundance of K. pneumoniae was greatly 
diminished at 1 month post-RBX2660 and remained lower than 
the pre-RBX2660 baseline at 4 months post-RBX2660 (but had 
increased relative to 1  month post-RBX2660), shortly before 
symptomatic recurrence (Figure 1B). Overall ARG abundance 
was reduced by >8-fold at 1 month post-RBX2660 administra-
tion, and β-lactamases, the most common class of resistance 
genes in the patient’s pre-RBX2660 microbiome (Figure  1C), 
were particularly diminished. Despite the patient’s concomitant 
exposure to broad-spectrum antibiotics for toe gangrene, ARG 
abundance did not rebound to the pre-RBX2660 baseline by 
4 months post-RBX2660 (Figure 1C).
RBX2660 Did Not Eliminate Uropathogen Carriage or UTI Recurrence After 
Antibiotics
MDR K.  pneumoniae carriage in the gut was diminished but 
not eliminated by RBX2660 (Figure 1B), and the patient expe-
rienced a UTI recurrence with MDR K. pneumoniae ~4 months 
post-RBX2660 after exposure to broad-spectrum antibiotics. 
Consistent with incomplete uropathogen clearance by RBX2660 
and subsequent reseeding from the gut [2, 10], a urine isolate 
collected during this recurrence differed by just 6 single nu-
cleotide polymorphisms (SNPs) from a K. pneumoniae stool 
isolate collected 1 day pre-RBX2660 (Figure 1D). Indeed, all 7 
K. pneumoniae isolates collected from the patient over >2 years 
had ≤30 pairwise SNPs, and a bloodstream isolate collected in 
January 2014 differed by only 3 SNPs from a urine isolate col-
lected in October 2015, 1  month post-RBX2660 (Figure  1D). 
All K. pneumoniae isolates, regardless of source, were also fully 
resistant to most antibiotics tested (Supplementary Table 1), 
with minor differences in susceptibility likely resulting from the 
acquisition of mobile genetic elements rather than from chro-
mosomal mutations.
The patient experienced an additional UTI ~6 weeks post-
RBX2660 that was caused by P.  mirabilis. This organism was 
not detectable in the patient’s stool before RBX2660 or in 
the RBX2660 preparation itself, suggesting acquisition inde-
pendent of intervention. Because this organism was nearly 
pan-susceptible to antibiotics (Supplementary Table 1), it was 
readily cleared by oral amoxicillin and did not recur.
DISCUSSION
Despite their significant clinical potential and increasing applica-
tion in medical practice, a singular definition of FMT “success” has 
not been established [11]. Historically, success has been defined as 
a positive clinical response, such as cessation of recurrent C. difficile 
infection. From a purely microbiological perspective, however, re-
versal of microbiome dysbiosis has also been considered a marker 
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always coincide. In this patient, increased microbiome richness and 
diversity after RBX2660 administration were not accompanied by 
complete uropathogen eradication, and there was a further recur-
rence of the patient’s MDR UTI after broad-spectrum antibiotic 
exposure. Although RBX2660 was well tolerated and mediated sub-
stantial microbiome diversification, the patient developed an acute 
UTI from P. mirabilis <2 months post-RBX2660. This infection was 
successfully treated with a narrow-spectrum oral antibiotic and did 
not recur, nor did it lead to a recurrence of MDR K. pneumoniae 
UTI. However, her chronic MDR K. pneumoniae UTI reemerged 
after an unrelated infection necessitated treatment with 7 different 
antibiotics, which may have selected for MDROs and contributed 
to UTI recurrence.
A critical but unanswerable question is whether this patient’s 
MDR K. pneumoniae UTI would have recurred in the absence 
of her toe gangrene and resulting antibiotic treatments. Before 
this unrelated infection, the patient had not experienced a 
K.  pneumoniae UTI recurrence for ~4  months, the longest 
such period without suppressive antibiotics within the previous 
2 years. Given the documented dissemination of uropathogens 
from the gut to the bladder [2, 10], microbiome-related mech-
anisms may have contributed to this UTI-free period, which oc-
curred despite the persistence of MDR K. pneumoniae in stool 
and urine at intervening asymptomatic time points. Nevertheless, 
we note that FMT recipients are often immunocompromised, 
develop secondary infections, and receive broad-spectrum anti-
biotics [12], and these comorbidities must be considered when 
defining, predicting, and evaluating FMT success or failure. We 
suggest that if microbiome restoration therapies do not fully erad-
icate causative MDROs from their intestinal reservoir(s), subse-
quent antibiotic treatments may enable re-emergence of these 
MDROs, regardless of the impact of FMT on other microbiome 
features. Because complete elimination of target MDROs by 
FMT may not always be achievable, however, this case also il-
lustrates the importance of further research into microbiome 
protectants [13] and microbiome–pathobiont–host interactions, 
which could minimize the likelihood of MDRO recurrence even 
in the absence of eradication. Larger studies should examine 
how comorbidities and antibiotics impact the clinical success of 
intestinal microbiota restoration therapies, as well as the broader 
relationship between microbiome recovery, MDRO clearance, 
and clinical progression following such therapies.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
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Figure 1. A, The patient experienced 3 episodes of urinary tract infection before RBX2660 (November 2013, January 2014, and June 2014, all from multidrug-resistant 
Klebsiella pneumoniae) and 2 episodes following RBX2660 (October 2015 from Proteus mirabilis and January 2016 from multidrug-resistant K. pneumoniae). The patient 
also experienced toe gangrene (TG; December 2015)  and asymptomatic bacteriuria (AB; April 2016). These infections necessitated treatment with meropenem (MEM), 
ertapenem (ETP), fosfomycin (FOF), amoxicillin (AMX), vancomycin (VAN), piperacillin + tazobactam (TZP), cefepime (FEP), metronidazole (MTZ), and amoxicillin + clavulanate 
(AMC). Stool and urine samples were collected for isolate and/or metagenomic sequencing at the designated time points. B, Stool microbiomes collected before and after 
RBX2660 administration, as well as the RBX2660 preparation itself, were profiled for relative abundance (left y-axis) and overall richness (right y-axis) of microbial species 
and for (C) total antibiotic resistance gene (ARG) count by class (left y-axis) and overall ARG abundance (right y-axis) (Supplementary Data). D, Phylogenetic relationships of 
multidrug-resistant K. pneumoniae isolates from stools, urines, and blood (sepsis) before and after RBX2660 administration were established by calculating single nucleotide 
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